Drug Repositioning by Mining Adverse Event Data in ClinicalTrials.gov

Area of Science:

• Computational biology
• Pharmacology
• Clinical informatics

Background:

• ClinicalTrials.gov contains extensive clinical study data.
• Mining clinical summary data offers research potential.
• Drug repositioning accelerates therapeutic development.

Purpose of the Study:

• To describe an in silico method for drug repositioning.
• To leverage serious adverse event data for identifying new drug uses.
• To explore the utility of ClinicalTrials.gov data for drug repurposing.

Main Methods:

• Utilizing an in silico approach for drug repositioning.
• Mining clinical summary data from ClinicalTrials.gov.
• Analyzing serious adverse event data to identify potential new drug applications.

Main Results:

• A protocol for in silico drug repositioning is described.
• Serious adverse event data can indicate potential new uses for drugs.
• ClinicalTrials.gov data is a valuable resource for this method.

Conclusions:

• The described in silico method enables drug repositioning.
• Analysis of adverse events in clinical trials can reveal novel therapeutic indications.
• This approach facilitates the repurposing of drugs and dietary supplements.